Using Endogenous Biomarkers to Derisk Assessment of Transporter‐Mediated Drug‐Drug Interactions: A Scientific Perspective-Reference-Cited by-同舟云学术

Using Endogenous Biomarkers to Derisk Assessment of Transporter‐Mediated Drug‐Drug Interactions: A Scientific Perspective

Published:2022-07-19 Issue:12 Volume:62 Page:1501-1506
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Arya Vikram¹,Reynolds Kellie S.¹,Yang Xinning²

Affiliation:

1. Division of Infectious Disease Pharmacology Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

2. Guidance and Policy Team Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2119

Reference36 articles.

1. Clinical Drug–Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access

2. Role of Transporters in Drug Development

3. Evaluation of transporters in drug development: Current status and contemporary issues

4. Regulatory Efforts to Facilitate Evaluation and Clinical Management of Drug‐Drug Interaction Risks

5. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme‐ and Transporter‐Mediated Drug Interactions Guidance for Industry. January2020.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of Biomarker‐Informed Drug Interaction Evaluation in Drug Development and Regulatory Decision Making;Clinical Pharmacology & Therapeutics;2024-09-09

2. Coproporphyrin‐I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug–Drug Interactions: Cedirogant Case Study;Clinical Pharmacology & Therapeutics;2024-08-05

3. Brightening the Path: Riboflavin Illuminates Breast Cancer Resistance Protein Monitoring;Journal of Pharmacology and Experimental Therapeutics;2024-07-18

4. Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier;Drug Metabolism Reviews;2024-07-05

5. Expanding Role of Endogenous Biomarkers for Assessment of Transporter Activity in Drug Development: Current Applications and Future Horizon;Pharmaceutics;2024-06-25